← Leaderboards
Brett C Ginsburg
Emory University
$4,439,764
Attributed
$5,970,856
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,970,856 · 11
By mechanism
R01$2,495,689 · 2
U01$2,296,638 · 1
R21$399,235 · 1
P30$385,152 · 2
R03$290,540 · 2
F31$68,870 · 1
Top collaborators
- Dean L Kellogg2 shared
- Ellen Kraig2 shared
Most similar at Emory University
Same institution · by research overlap
- John L. Hartman$5,755,869
- Leonard L Howell$20,665,111
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsRattusResponseFoodDrinkingEthanolBehavioralBrainBehaviorRecoveryAnimal ModelAlcohol AvailabilityStimulusPsychological ReinforcementProceduresRelapseTrainingInnovationExposure ToLearningPharmacologyAnteriorAlcohol EffectHippocampus (Brain)
Grant awards (23)
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An exploratory PK/PD study of mTOR inhibition in older human subjects$1,232,321
U01 · FY2025 · AG
Pharmacology and Drug Design Core$216,563
P30 · FY2025 · AG · contact PI
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An exploratory PK/PD study of mTOR inhibition in older human subjects$1,064,317
U01 · FY2024 · AG
Analytical Pharmacology and Drug Evaluation Core$168,589
P30 · FY2024 · AG · contact PI
Cognitive flexibility as a target for relapse prevention$341,235
R01 · FY2022 · AA · contact PI
Cognitive flexibility as a target for relapse prevention$341,235
R01 · FY2021 · AA · contact PI
Cognitive flexibility as a target for relapse prevention$341,235
R01 · FY2020 · AA · contact PI
Cognitive flexibility as a target for relapse prevention$341,235
R01 · FY2019 · AA · contact PI
Cognitive flexibility as a target for relapse prevention$341,235
R01 · FY2018 · AA · contact PI
Attentional bias to alcohol cues in rats: development and decline$181,094
R21 · FY2016 · AA · contact PI
Attentional bias to alcohol cues in rats: development and decline$218,141
R21 · FY2015 · AA · contact PI
Reinstatement of drug-maintained behavior suppressed by extinction or an availabl$190,769
R01 · FY2011 · AA · contact PI
Reinstatement of drug-maintained behavior suppressed by extinction or an availabl$198,470
R01 · FY2010 · AA · contact PI
Reinstatement of drug-maintained behavior suppressed by extinction or an availabl$200,475
R01 · FY2009 · AA · contact PI
Reinstatement of drug-maintained behavior suppressed by extinction or an availabl$199,800
R01 · FY2008 · AA · contact PI
Models for examining selective effects of pharmacotherapy on reinforced behaviors$73,000
R03 · FY2008 · AA · contact PI
Age, ethanol, and strain effects on the behavioral pharmacology of cannabinoids$71,540
R03 · FY2008 · DA · contact PI
Age, ethanol, and strain effects on the behavioral pharmacology of cannabinoids$73,000
R03 · FY2007 · DA · contact PI
Models for examining selective effects of pharmacotherapy on reinforced behaviors$73,000
R03 · FY2007 · AA · contact PI
MONOAMINE FUNCTION IN SQUIRREL MONKEY DURING COCAINE USE$18,585
P51 · FY2004 · RR
MONOAMINE FUNCTION IN SQUIRREL DURING COCAINE USE$16,147
P51 · FY2003 · RR
MONOAMINE FUNCTION IN MONKEYS DURING COCAINE USE$35,105
F31 · FY2001 · DA
MONOAMINE FUNCTION IN MONKEYS DURING COCAINE USE$33,765
F31 · FY2000 · DA